Stacey Greenwell-Osborne
Family · Bardstown, KYNPI 1356809768
Payments from drug & device makers
Across 159 payments — averaging $15.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$452
- AbbVie$352
- Novo Nordisk$321
- Lilly USA, LLC$290
- AstraZeneca$113
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$105
- plus $840 from 22 others
What the payments were for
- Food & beverage$2,473100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 33 | $452 |
| AbbVie | 20 | $352 |
| Novo Nordisk | 23 | $321 |
| Lilly USA, LLC | 18 | $290 |
| AstraZeneca | 8 | $113 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 6 | $105 |
| GSK | 7 | $102 |
| Amgen | 5 | $98 |
| Exact Sciences | 6 | $86 |
| Boehringer Ingelheim | 4 | $69 |
| Novartis | 4 | $69 |
| Astellas Pharma US Inc | 3 | $48 |
| Boston Scientific | 2 | $38 |
| Sanofi-aventis U.S. LLC | 3 | $38 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $33 |
| Axsome Therapeutics, Inc. | 1 | $33 |
| Corcept Therapeutics | 2 | $32 |
| Merck | 2 | $26 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $24 |
| Mylan Specialty L.p. | 1 | $22 |
| E.r. Squibb & Sons, L.L.C. | 1 | $21 |
| Bayer | 1 | $19 |
| Abbott | 1 | $17 |
| Vanda Pharmaceuticals Inc. | 1 | $16 |
| Inspire Medical Systems, Inc. | 1 | $14 |
| Ferring Pharmaceuticals Inc. | 1 | $14 |
| Si-bone, Inc. | 1 | $11 |
| Genentech USA, Inc. | 1 | $9 |
How this compares
$2,473 in reported general payments places this provider in the 80th percentile of 4,374 family providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 62 | $113,718 |
| JardianceEmpagliflozin | 55 | $59,288 |
| Nurtec OdtRimegepant Sulfate | 11 | $22,064 |
| MounjaroTirzepatide | 14 | $19,670 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 16 | $18,509 |
| XareltoRivaroxaban | 14 | $18,193 |
| EliquisApixaban | 18 | $17,453 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 15 | $12,175 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 11 | $8,150 |
| Varenicline Tartrate | 15 | $3,218 |
| Ventolin HfaAlbuterol Sulfate | 19 | $1,994 |
| Duloxetine Hcl | 68 | $1,463 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 64 | $1,301 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 15 | $1,259 |
| Levothyroxine Sodium | 156 | $1,203 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $321 | $113,71862 claims |
| Boehringer IngelheimJardiance, Stiolto Respimat | $69 | $67,43966 claims |
| PfizerNurtec Odt, Eliquis | $452 | $39,51729 claims |
| Lilly USA, LLCMounjaro | $290 | $19,67014 claims |
| GSKTrelegy Ellipta | $102 | $18,50916 claims |
| AbbVieSynthroid | $352 | $1,16925 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,374 family providers in Kentucky.
Other family in Bardstown
- Dale VincentBardstown$28K
- Bonnie HillLouisa$372K
- Ashley SnellenElizabethtown$190K
- Smita RanjanLouisville$92K
- Elizabeth SaltLexington$89K
- Tracey GaslinLouisville$79K
- Kassandra GreenLouisville$69K
- Danielle RevertLouisville$65K
- Lora BrownMonticellow$61K
- Shelley WaldmanLouisville$59K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.